4.5 Review

The role of the central nervous system in the generation and maintenance of chronic pain in rheumatoid arthritis, osteoarthritis and fibromyalgia

Journal

ARTHRITIS RESEARCH & THERAPY
Volume 13, Issue 2, Pages -

Publisher

BIOMED CENTRAL LTD
DOI: 10.1186/ar3306

Keywords

-

Categories

Funding

  1. Forest Laboratories
  2. holds stocks in Merck and Company, Inc.
  3. Novartis
  4. Elan Corporation
  5. Pfizer
  6. Cypress Bioscience, and Forest
  7. NIH/NIAMS [AR057578]
  8. NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K23AR057578] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Pain is a key component of most rheumatologic diseases. In fibromyalgia, the importance of central nervous system pain mechanisms (for example, loss of descending analgesic activity and central sensitization) is well documented. A few studies have also noted alterations in central pain processing in osteoarthritis, and some data, including the observation of widespread pain sensitivity, suggest that central pain-processing defects may alter the pain response in rheumatoid arthritis patients. When central pain is identified, different classes of analgesics (for example, serotonin-norepinephrine reuptake inhibitors, alpha(2)delta ligands) may be more effective than drugs that treat peripheral or nociceptive pain (for example, nonsteroidal anti-inflammatory drugs and opioids).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available